Falls in old and senile age is one of the main geriatric syndromes that determine the prognosis of a patient's life and autonomy, regardless of the consequences. According to experts, 33% of people 65 years of age and older have a history of falls, with 50% of them falling more than once a year. The prevalence of falls depends on the environment of older person: falls rate is more than 10 times higher for older people in nursing homes and hospitals than in those living at home. For people 65 years of age and older, falls is the most common cause of injury and the leading cause of death due to traumatic injury. Falls are closely related to other geriatric syndromes. It is important to understand that falls are preventable. Falls prevention is an integral part management of older and senile patients management.
Antipsychotic drugs are widely used for many psychiatric disorders, such as schizophrenia, bipolar affective disorder, delusions and hallucinations due to neurological disorders, depression with severe psychotic symptoms. Metabolic disorders including weight gain, dyslipidemia and hyperglycemia are one of the most common side effects of antipsychotic therapy. Psychiatric patients have higher risk of cardiovascular disease, so that the development of metabolic side effects is an important clinical problem that should be solved. Antipsychotic-induced weight gain may cause distress that leads to antipsychotics withdraw and repeated hospitalizations.Lifestyle changes, correction of the antipsychotic treatment, additional medications and their combination are the possible solutions of antipsychotic metabolic side effects. Lifestyle modification is a first-line therapy that should complement other options, when it feasible. At the same time, it can be extremely difficult for patients receiving antipsychotic to adhere dietary and physical activity recommendations. Replacing an antipsychotic with a milder drug is not always possible and may not be enough effective. Metformin seems to be the most well-studied, safe and effective agent that is prescribed to deal with antipsychotic-induced weight gain and associated metabolic disorders. Glucagon-like peptide type 1 receptor agonists and thiazolidinediones are mentioned as alternative medications, but clinical data on their efficacy and safety in this patient group are extremely limited. Dyslipidemia can develop as an independent antipsychotic side effect even without an increase in body weight. The most effective treatment, as in the general population, is statin therapy. However, the joint appointment of statins and antipsychotic significantly increases the risk of adverse reactions, such as myalgia, myopathy, increased creatine kinase levels, due to the competition of drugs for the cytochrome system.It is still unknown what scales should be used for cardiovascular risk stratification in patients taking antipsychotic and whether it is possible to use metformin to prevent antipsychotic-induced weight gain, and if so, how to select patients for whom such therapy can be indicated. Finally, more clinical trials are needed to evaluate the efficacy and safety of other classes of hypoglycemic and lipid-lowering drugs in patients on antipsychotics.
Summary
: Osteoporosis is associated with almost all geriatric syndromes (GSs), and the occurrence of osteoporosis in patients over 65 years of age increases by 1.2–2.5 times. Early diagnosis of osteoporosis and GSs is very important. Additional programs should be adopted by the state to introduce information about the possibilities of working with elderly patients. Purpose: To analyze associations of osteoporosis with geriatric syndromes in patients aged 65 years and older in the Russian Federation. Methods: A total of 4308 patients (30% men) aged 65–107 years were examined and distributed into 3 age groups (65–74 years, 75–84 years, and 85 years and older). All patients underwent a comprehensive geriatric assessment. In the “Falls and risk of falls” module, the number and circumstances of falls over the previous year were analyzed, as well as the history of fractures. The presence of osteoporosis was determined based on medical records. Physical examination included anthropometric measurements and standard enquiry, short physical performance battery (SPPB), dynamometry, measurement of gait velocity, Mini-Cog test, and orthostatic test. Results: A total of 507 patients (11.8%) had evidence of osteoporosis; indications of low-energy fractures in history were recorded in 739 (17.3%) patients. Patients with osteoporosis were older, shorter, and predominantly women; had a lower body weight and a higher Charlson comorbidity index; and took more drugs. Patients with osteoporosis had lower gait velocity, hand grip strength, Barthel index value, and scores of the Lawton instrumental activities of daily living scale, the MNA (Mini Nutritional Assessment) short-form, and the SPPB. Osteoporosis is associated with almost all geriatric syndromes (GSs), and the occurrence of osteoporosis in patients over 65 years of age increases by 1.2–2.5 times. Conclusions: Osteoporosis is associated with almost all GSs. The association of osteoporosis with advanced GSs aggravates the condition of these patients. Early diagnosis of osteoporosis and GSs is very important. Additional programs should be adopted by the state to introduce information about the possibilities of working with elderly patients: early detection and correction of osteoporosis.
15 September 2021 in Cardiovascular Drugs and Therapy
One of the most important trends in geroscience is the search for the biomechanisms of aging and geroprotective methods. In recent years, more and more attention has been paid to the role of age-related decline in IGF-1 levels; processes that start with a decrease in the activity of the GH/IGF-1 axis. IGF-1 levels correlate differently with many age-associated diseases: diabetes mellitus, cancer, cardiovascular disease. A decrease in the level of IGF-1 and growth hormone in the elderly can contribute to the deterioration of the course of some pathologies, and also have a protective effect in the occurrence of different nosologies. The possibility of slowing down aging with the help of IGF-1 in basic research led to research aimed at studying the possibility of using IGF-1 preparations and growth hormone in clinical practice to slow down aging. We have studied the literature on the Pubmed platform, Scopus for the past 10 years in order to find some new information regarding influence of IGF-1 on aging, about the association between IGF-1 levels and major age-related diseases. We analyzed data of publications on the role of IGF-1 in aging and the development of age-related diseases. The search was carried out using key words: IGF-1, growth hormone, aging, the review included data from more than 60 publications.
17 January 2024 in Russian Journal of Geriatric Medicine
Background. Life expectancy is increasing around the globe. However, chronological age is not the best indicator of health. For a more accurate assessment of body condition throughout life, in general, and aging, in particular, and identify potential points of geroprotective intervention, a specialized tool is needed. A tool that could prove beneficial is a biological age calculator, utilizing a range of biomarkers to analyze the degree of functional preservation of the body. Many existing biological age calculators are limited by a small number of parameters to analyze and sensitivity to use in a specific population.Aim. Large-scale studies to create a mathematical model for calculating biological age based on the Russian population have not previously been carried out. In 2022, the RUSS-AGE study was launched to create biochemical, cognitive and microbiotic calculators of biological age and determine possible points of geroprotective interventions.Materials and methods. The study intends to enroll at least 3,500 participants and analyze more than a hundred biomarkers using laboratory tests, questionnaires, neurocognitive and functional testing, and collection of anthropometric and physical indicators.Results. Currently, the recruitment of participants is supported by a government grant under the Priority 2030 program. By November 2023, 510 participants had been enrolled in the study.Conclusion. Further statistical processing of the information received and the development of prototypes of biological age calculators are planned.